SABS:NASDAQ, SAB Biotherapeutics, Inc.

SABS stock overview

SAB Biotherapeutics, Inc. (SABS:NASDAQ) closed at $2.96 on November 13, 2026, down 3.90% on the day. The stock trades 42.5% below its 52-week high of $5.15 and 21.3% above its 52-week low of $2.44. Over the past year, it lost 15.4%. SAB Biotherapeutics, Inc. is part of the Health Care sector.

Key figures

Price
$2.96
Day change
-3.90%
Volume
658,118
Average volume
588,385
Market cap
266M+
52-week range
$2.44 – $5.15
50-day average
$3.14
200-day average
$3.64

Price action over the past year

In 252 trading sessions since November 13, 2025, SABS closed higher on 114 days (45%). Its best day was June 15, 2026 (+17.12%) and its worst was December 8, 2025 (-10.80%). The stock moved 10% or more in a single session 6 times.

Recent signals

SABS news

About SAB Biotherapeutics, Inc.

SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company advancing a class of immunotherapies based on its human polyclonal antibodies. It develops fully human antibodies produced from transchromosomic (Tc) bovine herds targeted at addressing specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer.

Similar stocks

Find more stocks like SABS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.